Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
Abbott India Ltd has registered a 88.64 per cent rise in net profit at Rs 19.43 crore (Rs 194.3 million) for the first quarter ended February 29 compared to Rs 10.3 crore
The market regulator's newly proposed selection criteria for the over Rs 400-trillion-a-day futures and options (F&O) market could pave the way for the entry of popular stocks such as Life Insurance Corporation (LIC) of India, Jio Financial Services, Zomato, Paytm, DMart, and Adani Energy into the derivatives segment. The Indian derivatives market, which accounts for most of the trading volumes, could see big churn with over two dozen exits from the current list of 182 stocks due to an upward revision in the eligibility thresholds.
Abbott India Ltd has posted a net profit of Rs 144.15 million for the quarter ended November 30, 2002 as compared to a net profit of Rs 77.50 million for the quarter ended November 30, 2001.
Abbott India outperformed the Indian pharmaceutical market (IPM) with a year-on-year (YoY) growth of 23 per cent in February. The domestic market grew at a robust 20 per cent on a low base, primarily led by volume growth and price hikes. Abbott continued to outperform the sector in the anti-diabetic space with a growth of 20 per cent and key brands such as Thyronorm (hypothyroidism), biliary agent Udiliv, insulin Ryzodeg posted robust growth.
The National Stock Exchange (NSE) Nifty Next 50 Index could undergo large-scale changes if the proposed tweaks to its computation methodology get implemented. In a discussion paper floated recently, NSE Indices, which owns and manages a portfolio of over 350 indices under the Nifty brand, proposed that only stocks that are traded in the futures and options (F&O) segment can be part of the index. Currently, as many as 11 non-F&O stocks are part of the Nifty Next 50 Index, which, as the name suggests, represents the next rung of large and liquid securities after the Nifty50.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ten months after new Sebi norms set in, some senior directors still hold more board seats than allowed.
The merger of Pfizer and Wyeth is expected to create the second-biggest drug maker among multinational companies in India. The world's largest drug maker Pfizer yesterday announced a $68-billion acquisition of US-based Wyeth.
75 companies can dole out Rs 1.1 trillion from the 'extra cash' to shareholders.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
It is the fundamentals of companies that will drive stock performance.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Markets extended gains for the fourth consecutive day tracking gains in banks, capital goods and oil and gas majors.
Almost a third of the company's capex was stuck in this project
Proposed investment dip 33% from Rs 1.42 lakh crore (Rs 1.42 trillion) in 2011 to Rs 94,259 crore (Rs 942.59 billion) in 2013
The Sensex closed down 308 points at 24,894 and the Nifty has lost 96 points at 7,559.
The branding initiative coincides with the company's expansion.
India battles big pharma over cough syrup abuse, reducing supplies
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances